(DBV) DBV Technologies S.A. - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: PA (France) | Market Cap: 957m EUR | Total Return: 105.8% in 12m
Avg Turnover: 2.32M
Qual. Beats: 0
Rev. Trend: -43.3%
Qual. Beats: -1
Warnings
Share dilution 317.4% YoY
Interest Coverage Ratio -263.7 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
DBV Technologies S.A. is a clinical-stage biopharmaceutical firm based in France specializing in epicutaneous immunotherapy. The company utilizes its proprietary Viaskin technology platform to deliver allergens through the skin to desensitize patients, focusing primarily on food allergies such as peanut and cows milk protein. Its lead candidate, Viaskin Peanut, has completed Phase 3 trials, while Viaskin Milk remains in Phase 1/2 development.
The biotechnology sector often involves high research and development costs and lengthy regulatory approval processes before commercialization. DBV operates on a platform-based business model, allowing it to apply its patch technology across multiple indications, including celiac disease and diagnostic tools developed in collaboration with partners like Nestlé Health Science. Examining the technical analysis on ValueRay can provide further context for your investment thesis. This approach aims to address the underlying causes of allergies rather than merely managing acute symptoms.
- FDA regulatory approval timeline for Viaskin Peanut patch drives valuation
- Clinical trial data readouts for Viaskin Milk determine pipeline expansion
- Cash runway and potential capital raises impact near-term share dilution
- Strategic partnership with Nestlé Health Science influences commercialization scale
- Success of epicutaneous immunotherapy platform validates long-term technology moat
| Net Income: -167.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA 121.8 > 1.0 |
| NWC/Revenue: 3.46k% < 20% (prev -321.3%; Δ 3.78k% < -1%) |
| CFO/TA -0.57 > 3% & CFO -151.1m > Net Income -167.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (428.3m) vs 12m ago 317.4% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 3.56% > 50% (prev 6.92%; Δ -3.36% > 0%) |
| Interest Coverage Ratio: -263.7 > 6 (EBITDA TTM -158.2m / Interest Expense TTM 648k) |
| A: 0.73 (Total Current Assets 246.7m - Total Current Liabilities 51.8m) / Total Assets 266.4m |
| B: -1.65 (Retained Earnings -440.7m / Total Assets 266.4m) |
| C: -1.08 (EBIT TTM -170.9m / Avg Total Assets 158.5m) |
| D: -7.12 (Book Value of Equity -416.6m / Total Liabilities 58.5m) |
| Altman-Z'' = -15.32 = D |
| DSRI: 0.76 (Receivables 15.1m/12.3m, Revenue 5.64m/3.50m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.21 (AQ_t 0.02 / AQ_t-1 0.10) |
| SGI: 1.61 (Revenue 5.64m / 3.50m) |
| TATA: -0.06 (NI -167.7m - CFO -151.1m) / TA 266.4m) |
| Beneish M = -3.31 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at EUR 3.20 with a total of 549,214 shares traded.
Over the past week, the price has changed by -5.07%,
over one month by -5.07%,
over three months by -10.99% and
over the past year by +105.82%.
DBV Technologies S.A. has no consensus analysts rating.
Market Cap USD = 1.11b (957.4m EUR * 1.1625 EUR.USD)
P/S = 166.911
P/B = 5.3389
Revenue TTM = 5.64m USD
EBIT TTM = -170.9m USD
EBITDA TTM = -158.2m USD
Long Term Debt = 5.41m USD (from longTermDebtTotal, last fiscal year)
Short Term Debt = 12.2m USD (from shortTermDebt, last quarter)
Debt = 6.10m USD (from shortLongTermDebtTotal, last quarter) (leases 6.10m already included)
Net Debt = -223.1m USD (calculated: Debt 6.10m - CCE 229.2m)
Enterprise Value = 889.9m USD (1.11b + Debt 6.10m - CCE 229.2m)
Interest Coverage Ratio = -263.7 (Ebit TTM -170.9m / Interest Expense TTM 648k)
EV/FCF = -5.85x (Enterprise Value 889.9m / FCF TTM -152.1m)
FCF Yield = -17.09% (FCF TTM -152.1m / Enterprise Value 889.9m)
FCF Margin = -2.70k% (FCF TTM -152.1m / Revenue TTM 5.64m)
Net Margin = -2.98k% (Net Income TTM -167.7m / Revenue TTM 5.64m)
Gross Margin = unknown ((Revenue TTM 5.64m - Cost of Revenue TTM 18.3m) / Revenue TTM)
Tobins Q-Ratio = 3.34 (Enterprise Value 889.9m / Total Assets 266.4m)
Interest Expense / Debt = 10.62% (Interest Expense 648k / Debt 6.10m)
Taxrate = 21.0% (US default 21%)
NOPAT = -135.0m (EBIT -170.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.76 (Total Current Assets 246.7m / Total Current Liabilities 51.8m)
Debt / Equity = 0.03 (Debt 6.10m / totalStockholderEquity, last quarter 208.0m)
Debt / EBITDA = 1.41 (negative EBITDA) (Net Debt -223.1m / EBITDA -158.2m)
Debt / FCF = 1.47 (negative FCF - burning cash) (Net Debt -223.1m / FCF TTM -152.1m)
Total Stockholder Equity = 129.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -105.8% (out of range, set to none)
RoE = -29.44% (Net Income TTM -167.7m / Total Stockholder Equity 569.7m)
RoCE = -29.72% (EBIT -170.9m / Capital Employed (Equity 569.7m + L.T.Debt 5.41m))
RoIC = -66.68% (negative operating profit) (NOPAT -135.0m / Invested Capital 202.5m)
WACC = 5.70% (E(1.11b)/V(1.12b) * Re(5.69%) + D(6.10m)/V(1.12b) * Rd(10.62%) * (1-Tc(0.21)))
Discount Rate = 5.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 69.01 | Cagr: 94.31%
[DCF] Fair Price = unknown (Cash Flow -152.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.52 | # QB: 0
Revenue Correlation: -43.25 | Revenue CAGR: -24.14% | SUE: -1.09 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.09 | Chg30d=+18.27% | Revisions=+20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.08 | Chg30d=+10.47% | Revisions=+20% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.20 | Chg30d=N/A | Revisions=+20% | GrowthEPS=+56.5% | GrowthRev=-24.3%
EPS next Year (2027-12-31): EPS=-0.08 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+57.6% | GrowthRev=+2025.4%